title: Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
abstract: BACKGROUND
  In North America, Borrelia burgdorferi is the causative bacterial agent of canine Lyme borreliosis and is transmitted following prolonged attachment and feeding of vector ticks, Ixodes scapularis or Ixodes pacificus. Its prevention is predicated upon tick-avoidance, effective on-animal tick control and effective immunization strategies. The purpose of this study is to characterize dogs that are newly seropositive for Borrelia burgdorferi infection in relation to compliant use of a recombinant OspA canine Lyme borreliosis vaccine. Specifically, Preventive Fractions (PF) and Risk Ratios (RR) associated with the degree of vaccine compliancy (complete versus incomplete) are determined.
  
  
  METHODS
  6,202 dogs were tested over a five year period in a single veterinary hospital utilizing a non-adjuvanted, recombinant OspA vaccine according to a 0, 1, 6 month (then yearly) protocol. Rates of newly acquired "Lyme-positive" antibody test results were compared between protocol compliant and poorly compliant (incompletely and/or non-vaccinated) dogs.
  
  
  RESULTS
  Over the five-year span, one percent (range 0.39 - 1.3) of protocol compliant vaccinated, previously antibody negative dogs became seropositive for infection. Approximately twenty-one percent (range 16.8 - 33.3) of incompletely vaccinated dogs became positive for infection-specific antibodies. The Preventative Fraction for testing positive for antibodies specific for infection with Borrelia burgdorferi in any given year based on optimal vaccine compliance was, on average, 95.3% (range 93.29 - 98.08). The Risk Ratio for becoming infected with Borrelia burgdorferi antibodies in any given year if vaccine non-compliant was 21.41 (range 14.9 - 52.1). There was a high statistically significant relationship (p = <0.0001) in the observed data in terms of vaccination protocol compliance and the probability of Borrelia burgdorferi infection in each of the five years under study.
  
  
  CONCLUSIONS
  The recombinant outer surface protein A (rOspA) vaccine for dogs is highly effective in preventing new seropositive cases of Borrelia burgdoferi infection over a five-year period in dogs living in an endemic area. Dogs that were vaccine protocol-compliant were significantly less likely to become infected (as indirectly assessed by antibody) with the agent of canine Lyme borreliosis as measured by Preventive Fraction and Risk Ratio calculations.
authors.affiliation: Merial Limited, 3239 Satellite Boulevard NW, Duluth, GA, 30096, USA. drandrew.eschner@merial.com.
authors.forename: Andrew K
authors.initials: AK
authors.lastname: Eschner
authors.affiliation: Coastal Veterinary Care, 161 Gardiner Road, Wiscasset, ME, 04578, USA. CoastalVetCare@roadrunner.com.
authors.forename: Kristen
authors.initials: K
authors.lastname: Mugnai
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000954:Antigens, Surface / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D025065:Borrelia burgdorferi / Q000235:genetics / Q000276:immunology*; D004283:Dog Diseases / Q000453:epidemiology / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D004285:Dogs; D007114:Immunization; D008074:Lipoproteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D008193:Lyme Disease / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D008281:Maine / Q000453:epidemiology
chemical_list: D000907:Antibodies, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; C072045:OspA protein